BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sung WW, Wang SC, Hsieh TY, Ho CJ, Huang CY, Kao YL, Chen WJ, Chen SL. Favorable mortality-to-incidence ratios of kidney Cancer are associated with advanced health care systems. BMC Cancer 2018;18:792. [PMID: 30081855 DOI: 10.1186/s12885-018-4698-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Kuang XH, Zhang Y, Hu DM, Liu K. Global burden of gastric cancer in adolescents and young adults: estimates from GLOBOCAN 2020. Public Health 2022;210:58-64. [PMID: 35870322 DOI: 10.1016/j.puhe.2022.06.010] [Reference Citation Analysis]
2 Li J. Digestive cancer incidence and mortality among young adults worldwide in 2020: A population-based study. World J Gastrointest Oncol 2022;14:278-94. [PMID: 35116117 DOI: 10.4251/wjgo.v14.i1.278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang CC, Sung WW, Yan PY, Ko PY, Tsai MC. Favorable colorectal cancer mortality-to-incidence ratios in countries with high expenditures on health and development index: A study based on GLOBOCAN database. Medicine (Baltimore) 2021;100:e27414. [PMID: 34731114 DOI: 10.1097/MD.0000000000027414] [Reference Citation Analysis]
4 Yang TW, Wang CC, Hung WC, Liu YH, Sung WW, Tsai MC. Improvement in the Mortality-to-Incidence Ratios for Gastric Cancer in Developed Countries With High Health Expenditures. Front Public Health 2021;9:713895. [PMID: 34485236 DOI: 10.3389/fpubh.2021.713895] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sung WW, Hsu YC, Dong C, Chen YC, Chao YC, Chen CJ. Favorable Lip and Oral Cancer Mortality-to-Incidence Ratios in Countries with High Human Development Index and Expenditures on Health. Int J Environ Res Public Health 2021;18:6012. [PMID: 34205053 DOI: 10.3390/ijerph18116012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Sung WW, Au KK, Wu HR, Yu CY, Wang YC. Improved trends of lung cancer mortality-to-incidence ratios in countries with high healthcare expenditure. Thorac Cancer 2021;12:1656-61. [PMID: 33829674 DOI: 10.1111/1759-7714.13912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Georgantopoulos P, Eberth JM, Cai B, Rao G, Bennett CL, Emrich CT, Haddock KS, Hébert JR. A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999-2015. Ann Epidemiol 2021;59:24-32. [PMID: 33836289 DOI: 10.1016/j.annepidem.2021.03.010] [Reference Citation Analysis]
8 Huang CY, Wang SC, Chan L, Hsieh TY, Sung WW, Chen SL. Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries. PLoS One 2021;16:e0244510. [PMID: 33577604 DOI: 10.1371/journal.pone.0244510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wang SC, Chang NW, Chen WJ, Yang MH, Chen SL, Sung WW. Trends of Testicular Cancer Mortality-to-Incidence Ratios in Relation to Health Expenditure: An Ecological Study of 54 Countries. Int J Environ Res Public Health 2021;18:1546. [PMID: 33561945 DOI: 10.3390/ijerph18041546] [Reference Citation Analysis]
10 Sung WW, Ko PY, Chen WJ, Wang SC, Chen SL. Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries. Sci Rep 2021;11:1479. [PMID: 33446693 DOI: 10.1038/s41598-020-79367-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang SC, Chan L, Hsieh TY, Wang CH, Chen SL, Sung WW. Limited improvement in prostate cancer mortality-to-incidence ratios in countries with high health care expenditures. Aging (Albany NY) 2020;12:21308-15. [PMID: 33216731 DOI: 10.18632/aging.103865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee YC, Calderon-Candelario RA, Holt GE, Campos MA, Mirsaeidi M. State-Level Disparity in Lung Cancer Survival in the United States. Front Oncol 2020;10:1449. [PMID: 32974167 DOI: 10.3389/fonc.2020.01449] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Trapani D, Curigliano G, Alexandru E, Sternberg CN. The global landscape of drug development for kidney cancer. Cancer Treat Rev 2020;89:102061. [PMID: 32738737 DOI: 10.1016/j.ctrv.2020.102061] [Reference Citation Analysis]
14 Papanikolaou D, Ioannidou P, Koukourikis P, Moysidis K, Meditskou S, Koutsoumparis D, Hatzimouratidis K, Hatzivassiliou E. Systemic therapy for chromophobe renal cell carcinoma: A systematic review. Urol Oncol 2020;38:137-49. [PMID: 31953002 DOI: 10.1016/j.urolonc.2019.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]